Minimally invasive parenchyma-sparing pancreatectomy (mi-psp) lowers the risk of new-onset diabetes and pancreatic exocrine insufficiency in patients with benign and low-grade pancreatic tumors.

• Postoperative diabetes occurred in 9.8% of mi-psp patients compared to 23% in the standard approach (p=0.008).
• The five-year cumulative risk of diabetes was 26.7% for mi-psp versus 38.9% for the traditional method.
• Pancreatic exocrine insufficiency developed in only 5.4% of mi-psp patients, versus 22% for standard pancreatectomy (p=0.001).

This study supports mi-psp as a favorable option for minimizing metabolic complications post-surgery.